• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Marie Powers

Marie Powers

Articles

ARTICLES

Alpine makes smooth run to $48M series A for immunotherapy platform

June 14, 2016
By Marie Powers
A year after its founding, Alpine Immune Sciences Inc. (AIS) sped to a $48 million series A round that was led by Orbimed Advisors and joined by Frazier Healthcare Partners and Alpine Bioventures. In January 2015, Alpine Bio founded and provided the seed funding for Seattle-based AIS, which is developing protein-based immunotherapies using its variant immunoglobulin domain, or vIgD, platform technology, to interact simultaneously with multiple targets in the immune synapse using a single molecule.
Read More

How to price drug value? Payers, biopharma are still worlds apart

June 10, 2016
By Marie Powers

Panelists at Allicense 2016, held this year in conjunction with the 2016 BIO International Convention, made clear that the debate over drug cost valuation that escalated last year continues to rage.


Read More

Will biopharma deal-making brave the headwinds or retreat to 'wait-and-see'?

June 10, 2016
By Marie Powers
Following a record-breaking year for deal-makers, 2016 isn't exactly off to the races. The drug pricing debate, magnified through the lens of a contentious Presidential campaign, and mounting pressure on the industry's blue chips to improve performance in the midst of a volatile stock market have placed heavy demands on partnering activity. In a super session on the final day of the BIO International Convention, a panel of veteran deal-makers debated whether big biopharmas will take a wait-and-see approach or throw caution to the wind and forge ahead with partnering and M&A.
Read More

Another twist in eteplirsen saga gives Sarepta more rope, but to what end?

June 8, 2016
By Marie Powers
In a brief statement released following Monday's market close, Sarepta Therapeutics Inc. revealed that the FDA requested additional dystrophin data as part of its ongoing review of the new drug application (NDA) for Duchenne muscular dystrophy (DMD) candidate, eteplirsen. According to Sarepta, the agency said the dystrophin data, as measured by Western blot, could be acquired from biopsies already obtained from PROMOVI, the ongoing confirmatory study of eteplirsen.
Read More

Reports: Despite financial market turmoil, small biopharma still kicking

June 7, 2016
By Marie Powers
SAN FRANCISCO – In a presentation during the opening day of the BIO International Convention, industry veteran Dave Thomas, senior director of industry research for the Biotechnology Innovation Organization (BIO), took a deeper dive into findings from two recent industry reports that he co-authored.
Read More

Clearside Biomedical clears IPO runway, maintains altitude after low share pricing

June 6, 2016
By Marie Powers

Election year politics a wild card as biopharma weighs financing climate

June 6, 2016
By Marie Powers
SAN FRANCISCO – The crossover party is all but over. Pure public players have moved upstream. Companies that went public as recently as 2014 are going belly-up. And a hyperbolic presidential election campaign has turned the industry's life-saving mission into a source of public controversy.
Read More

Clearside clears IPO runway, maintains altitude after pricing low

June 3, 2016
By Marie Powers
Clearside Biomedical Inc. priced low but increased the shares in its IPO to take off about where it expected. The company offered 7.2 million common shares priced at $7 apiece to raise $50.4 million and granted underwriters a 30-day option to purchase up to 1.08 million additional shares to fill overallotments, potentially adding $7.56 million to the raise.
Read More

For the birds, or the BlackBerries: Titles to intrigue and entertain in BioWorld’s 10th Annual Summer Reading List

June 1, 2016
By Marie Powers
We’re still a few weeks away from the summer solstice, at least in the Northern Hemisphere, but with BIO around the corner that trip to San Francisco justifies a good read. Whether you’re in the mood for the story of a scientist coming of age or of a world leader seeking to thwart the Axis powers, a street child’s search for his father or a neurologist’s look at psychosomatic illness, BioWorld’s Summer Reading List – our 10th annual – is certain to have something to pique your interest. We culled the top suggestions from our writers and readers, in some...
Read More

Teva flunks orphan drug test with CRL on Auspex-developed chorea treatment

June 1, 2016
By Marie Powers
Another billion-dollar-plus deal failed to play out as planned as the FDA dealt Teva Pharmaceutical Industries Ltd. a complete response letter on its new drug application for SD-809 to treat chorea – involuntary writhing movements – associated with Huntington disease.
Read More
View All Articles by Marie Powers

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 9, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 9, 2025.
  • US flag, stock market chart, White House

    100 days of uncertainty

    BioWorld
    The first 100 days of the Trump administration have been nothing short of chaotic, both in the U.S. and throughout the world. Shining a light through the...
  • AI generated, 3D rendering of protein degradation

    AACR 2025: Induced proximity strategy, beyond degraders

    BioWorld
    Targeted protein degradation has yet to notch its first approval. But with more than two dozen agents now in clinical trials, the strategy’s ultimate clinical...
  • NME Digest: Q1 2025

    BioWorld
    A quarterly dynamic table featuring new molecular entities (NMEs) revealed for the first time in current literature, at congresses and in company communications...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe